Lifeloc Q3 net profit $110K, revenue up 33% to $2.696M; SpinDx beta in early 2024

Lifeloc Technologies, Inc

2023-Q3 EPS reported $0.05 revenue$7,140,408

Q3 2023 net profit $110K ($0.04 diluted EPS) vs net loss $(87K) ($(0.04) per share) in Q3 2022.
Q3 revenue $2.696M (+33% YoY); gross margin improved to 41.5% from 37.8%.
Nine-month net profit $111K ($0.05 EPS) vs net loss $(433K) ($(0.18) EPS) in prior year.
SpinDx THC saliva test beta expected early 2024, commercialization later 2024; R&D spending up 65%.
Production backlog satisfied as supply chain constraints significantly relieved during Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lifeloc Technologies, Inc reported third quarter ended September 30, 2023 results: revenue $2.696 million, net income $110 thousand, EPS $0.04 per diluted share.

Period: third quarter ended September 30, 2023
Revenue: $2.696 million
Net income: $110 thousand
EPS: $0.04 per diluted share
Result: reported results

Exact text from the filing

Lifeloc posted quarterly net revenue of $2.696 million in the third quarter of 2023, resulting in a quarterly net profit of $110 thousand, or $0.04 per diluted share.

View on SEC.gov

Browse all earnings releases →

Lifeloc Technologies, Inc filing history →

Source: SEC EDGAR

accession 0001079973-23-001538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.